Recently, “The 6th Future Healthcare 100 Conference” was successfully held online, with the theme of "China Story", aiming to gather the core strength of the industry, promote innovative health care industry changes, and create a platform for exchange and docking in the medical and health care industry chain, attracting nearly 200 experts from clinical, research, capital and industrial sectors attended the conference. On the evening of June 15, the 7th Future Medical 100 series list was announced. With outstanding industry influence, diversified industrial layout and promising development prospects, BRL Medicine was awarded " 2022 Future Healthcare VB100 · Innovative Biomedicine Companies TOP 100" and " 2022 Future Healthcare VB100 · Best-Performing Companies In Valuable Fields".

Figure 1: BRL Medicine was awarded " Innovative Biomedicine Companies TOP 100"

The VB100 is the first domestic list of innovative healthcare for non-listed companies launched by VCBeat Research(VCB). It aims to select Chinese innovative healthcare players that truly represent the future of healthcare, discover the core strengths of China's future healthcare industry, and promote the process of innovation and change in the healthcare industry.

Figure 2: BRL Medicine 2021 Trophy

After being awarded the 2021 Future Healthcare VB100 · Innovative Biomedicine Companies TOP 100 last year, BRL Medicine has again been ranked on the list, which not only reflects the comprehensive strength of BRL Medicine in innovation, R&D and global transformation in core technologies, as well as business model innovation, brand operation, strategic cooperation and public relations, but also signifies that the innovation power and future development potential shown by BRL Medicine have been recognized by the industry.

In the future, BRL Medicine will continue to adhere to technological innovation and strive to solve the core problems and technical problems encountered in gene and cell therapy, always with the mission of " Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world", committed to become the world's leading Cellular & Gene pharmaceutical company, and actively promote the development of CGT industry, and bringing good news to more patients with genetic and oncological diseases for the benefit of mankind.